Clinicopathologic and treatment characteristics
| Characteristic . | All patients (N = 19) . |
|---|---|
| Age, median (range), y | 69 (33-98) |
| Sex, no. (%) | |
| Female | 6 (32) |
| Male | 13 (68) |
| International Prognostic Index score, no. (%) | |
| <3 | 6 (32) |
| ≥3 | 13 (68) |
| Histologic classification, no. (%) | |
| DLBCL | 14 (74) |
| HGBL | 5 (26) |
| Prior low-grade lymphoma, no. (%) | |
| No | 14 (74) |
| Yes | 5 (26) |
| Ki67, median (range), % | 80 (50-95) |
| COO by Hans algorithm, no. (%) | |
| GCB | 4 (21) |
| NGC | 15 (79) |
| Fluorescence in situ hybridization, no. (%) | |
| MYC rearrangement present | 7/14 (50) |
| BCL2 rearrangement present | 3/12 (25) |
| BCL6 rearrangement present | 1/7 (14) |
| Double-hit lymphoma | 3 |
| MYD88 L265P mutation present | 1/6 (17) |
| Front-line chemotherapy, no. (%) | |
| R-CHOP | 14 (74) |
| Intensive | 5 (26) |
| Second-line therapy, no. (%) | |
| Curative-intent cytotoxic therapy | 10 (53) |
| Other cytotoxic therapy | 2 (10) |
| Ibrutinib | 3 (16) |
| Other noncytotoxic therapy | 4 (21) |
| Prior ASCT, no. (%) | |
| No | 11 (58) |
| Yes | 8 (42) |
| Ibrutinib as line of therapy, no. (%) | |
| Second | 3 (16) |
| Third | 8 (42) |
| Fourth | 4 (21) |
| ≥Fifth | 4 (21) |
| Duration from start of prior therapy to start of ibrutinib, no. (%), mo | |
| 0-6 | 15 (79) |
| 6-12 | 3 (16) |
| >12 | 1 (5) |
| Characteristic . | All patients (N = 19) . |
|---|---|
| Age, median (range), y | 69 (33-98) |
| Sex, no. (%) | |
| Female | 6 (32) |
| Male | 13 (68) |
| International Prognostic Index score, no. (%) | |
| <3 | 6 (32) |
| ≥3 | 13 (68) |
| Histologic classification, no. (%) | |
| DLBCL | 14 (74) |
| HGBL | 5 (26) |
| Prior low-grade lymphoma, no. (%) | |
| No | 14 (74) |
| Yes | 5 (26) |
| Ki67, median (range), % | 80 (50-95) |
| COO by Hans algorithm, no. (%) | |
| GCB | 4 (21) |
| NGC | 15 (79) |
| Fluorescence in situ hybridization, no. (%) | |
| MYC rearrangement present | 7/14 (50) |
| BCL2 rearrangement present | 3/12 (25) |
| BCL6 rearrangement present | 1/7 (14) |
| Double-hit lymphoma | 3 |
| MYD88 L265P mutation present | 1/6 (17) |
| Front-line chemotherapy, no. (%) | |
| R-CHOP | 14 (74) |
| Intensive | 5 (26) |
| Second-line therapy, no. (%) | |
| Curative-intent cytotoxic therapy | 10 (53) |
| Other cytotoxic therapy | 2 (10) |
| Ibrutinib | 3 (16) |
| Other noncytotoxic therapy | 4 (21) |
| Prior ASCT, no. (%) | |
| No | 11 (58) |
| Yes | 8 (42) |
| Ibrutinib as line of therapy, no. (%) | |
| Second | 3 (16) |
| Third | 8 (42) |
| Fourth | 4 (21) |
| ≥Fifth | 4 (21) |
| Duration from start of prior therapy to start of ibrutinib, no. (%), mo | |
| 0-6 | 15 (79) |
| 6-12 | 3 (16) |
| >12 | 1 (5) |